nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—colon cancer	0.751	1	CbGaD
Dihydroergotamine—ABCB1—Irinotecan—colon cancer	0.0141	0.284	CbGbCtD
Dihydroergotamine—ABCB1—Vincristine—colon cancer	0.0123	0.248	CbGbCtD
Dihydroergotamine—CYP3A4—Irinotecan—colon cancer	0.00845	0.17	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—colon cancer	0.00746	0.15	CbGbCtD
Dihydroergotamine—CYP3A4—Vincristine—colon cancer	0.00739	0.149	CbGbCtD
Dihydroergotamine—Ventricular fibrillation—Capecitabine—colon cancer	0.0016	0.0081	CcSEcCtD
Dihydroergotamine—Tingling sensation—Capecitabine—colon cancer	0.00152	0.00772	CcSEcCtD
Dihydroergotamine—Myocardial ischaemia—Capecitabine—colon cancer	0.00152	0.00772	CcSEcCtD
Dihydroergotamine—Euphoric mood—Fluorouracil—colon cancer	0.00151	0.00763	CcSEcCtD
Dihydroergotamine—Rigors—Capecitabine—colon cancer	0.0015	0.0076	CcSEcCtD
Dihydroergotamine—Petechiae—Capecitabine—colon cancer	0.00149	0.00754	CcSEcCtD
Dihydroergotamine—Injury—Irinotecan—colon cancer	0.00145	0.00732	CcSEcCtD
Dihydroergotamine—Swelling—Fluorouracil—colon cancer	0.00144	0.00731	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Capecitabine—colon cancer	0.00137	0.00692	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Irinotecan—colon cancer	0.00136	0.00687	CcSEcCtD
Dihydroergotamine—Herpes simplex—Capecitabine—colon cancer	0.00133	0.00673	CcSEcCtD
Dihydroergotamine—Gait disturbance—Capecitabine—colon cancer	0.00126	0.00636	CcSEcCtD
Dihydroergotamine—Hiccups—Capecitabine—colon cancer	0.00123	0.00621	CcSEcCtD
Dihydroergotamine—Stupor—Methotrexate—colon cancer	0.00122	0.00619	CcSEcCtD
Dihydroergotamine—Muscular weakness—Vincristine—colon cancer	0.0012	0.0061	CcSEcCtD
Dihydroergotamine—Cramp muscle—Irinotecan—colon cancer	0.0012	0.00606	CcSEcCtD
Dihydroergotamine—Influenza like illness—Capecitabine—colon cancer	0.00119	0.00603	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Capecitabine—colon cancer	0.00118	0.00599	CcSEcCtD
Dihydroergotamine—Muscular weakness—Fluorouracil—colon cancer	0.00112	0.00569	CcSEcCtD
Dihydroergotamine—Sweating increased—Irinotecan—colon cancer	0.00112	0.00567	CcSEcCtD
Dihydroergotamine—Angina pectoris—Irinotecan—colon cancer	0.00112	0.00567	CcSEcCtD
Dihydroergotamine—Petechiae—Methotrexate—colon cancer	0.00111	0.00562	CcSEcCtD
Dihydroergotamine—Dysphagia—Fluorouracil—colon cancer	0.0011	0.00557	CcSEcCtD
Dihydroergotamine—Angina pectoris—Fluorouracil—colon cancer	0.00107	0.00543	CcSEcCtD
Dihydroergotamine—Abnormal vision—Capecitabine—colon cancer	0.00107	0.00541	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Irinotecan—colon cancer	0.00107	0.00541	CcSEcCtD
Dihydroergotamine—Mental disability—Capecitabine—colon cancer	0.00106	0.00539	CcSEcCtD
Dihydroergotamine—Speech disorder—Methotrexate—colon cancer	0.00106	0.00537	CcSEcCtD
Dihydroergotamine—Ear pain—Capecitabine—colon cancer	0.00104	0.00528	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Vincristine—colon cancer	0.00104	0.00525	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Vincristine—colon cancer	0.00103	0.00522	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00102	0.00518	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Methotrexate—colon cancer	0.00102	0.00515	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Irinotecan—colon cancer	0.00101	0.00511	CcSEcCtD
Dihydroergotamine—Swelling—Capecitabine—colon cancer	0.00101	0.00511	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Irinotecan—colon cancer	0.001	0.00509	CcSEcCtD
Dihydroergotamine—Herpes simplex—Methotrexate—colon cancer	0.00099	0.00501	CcSEcCtD
Dihydroergotamine—Eye pain—Capecitabine—colon cancer	0.000985	0.00499	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Fluorouracil—colon cancer	0.000967	0.0049	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Fluorouracil—colon cancer	0.000961	0.00487	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Fluorouracil—colon cancer	0.000953	0.00483	CcSEcCtD
Dihydroergotamine—Hot flush—Capecitabine—colon cancer	0.000951	0.00482	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Capecitabine—colon cancer	0.000943	0.00477	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Vincristine—colon cancer	0.000939	0.00476	CcSEcCtD
Dihydroergotamine—Epistaxis—Fluorouracil—colon cancer	0.000925	0.00469	CcSEcCtD
Dihydroergotamine—Rhinitis—Irinotecan—colon cancer	0.000922	0.00467	CcSEcCtD
Dihydroergotamine—Sinusitis—Fluorouracil—colon cancer	0.00092	0.00466	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Methotrexate—colon cancer	0.000912	0.00462	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Capecitabine—colon cancer	0.000908	0.0046	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Methotrexate—colon cancer	0.000891	0.00451	CcSEcCtD
Dihydroergotamine—Visual impairment—Irinotecan—colon cancer	0.000886	0.00449	CcSEcCtD
Dihydroergotamine—Rhinitis—Fluorouracil—colon cancer	0.000883	0.00447	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Methotrexate—colon cancer	0.000881	0.00446	CcSEcCtD
Dihydroergotamine—Cystitis—Methotrexate—colon cancer	0.000881	0.00446	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Fluorouracil—colon cancer	0.000876	0.00444	CcSEcCtD
Dihydroergotamine—Migraine—Capecitabine—colon cancer	0.000875	0.00443	CcSEcCtD
Dihydroergotamine—Pharyngitis—Fluorouracil—colon cancer	0.000874	0.00443	CcSEcCtD
Dihydroergotamine—Vaginal infection—Methotrexate—colon cancer	0.000861	0.00436	CcSEcCtD
Dihydroergotamine—Face oedema—Capecitabine—colon cancer	0.000859	0.00435	CcSEcCtD
Dihydroergotamine—Flushing—Irinotecan—colon cancer	0.000853	0.00432	CcSEcCtD
Dihydroergotamine—Chills—Irinotecan—colon cancer	0.000825	0.00418	CcSEcCtD
Dihydroergotamine—Bladder pain—Methotrexate—colon cancer	0.000825	0.00418	CcSEcCtD
Dihydroergotamine—Ergotamine—ABCB1—colon cancer	0.000793	0.509	CrCbGaD
Dihydroergotamine—Muscular weakness—Capecitabine—colon cancer	0.000784	0.00397	CcSEcCtD
Dihydroergotamine—Muscle spasms—Irinotecan—colon cancer	0.000769	0.0039	CcSEcCtD
Dihydroergotamine—Dysphagia—Capecitabine—colon cancer	0.000769	0.00389	CcSEcCtD
Dihydroergotamine—Bromocriptine—ABCB1—colon cancer	0.000765	0.491	CrCbGaD
Dihydroergotamine—Bronchospasm—Capecitabine—colon cancer	0.000756	0.00383	CcSEcCtD
Dihydroergotamine—Agitation—Vincristine—colon cancer	0.000755	0.00383	CcSEcCtD
Dihydroergotamine—Sweating increased—Capecitabine—colon cancer	0.000749	0.00379	CcSEcCtD
Dihydroergotamine—Angina pectoris—Capecitabine—colon cancer	0.000749	0.00379	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Irinotecan—colon cancer	0.000743	0.00376	CcSEcCtD
Dihydroergotamine—Bronchitis—Capecitabine—colon cancer	0.000739	0.00374	CcSEcCtD
Dihydroergotamine—Vertigo—Vincristine—colon cancer	0.000738	0.00374	CcSEcCtD
Dihydroergotamine—Malaise—Irinotecan—colon cancer	0.000722	0.00366	CcSEcCtD
Dihydroergotamine—Vertigo—Irinotecan—colon cancer	0.000719	0.00364	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Capecitabine—colon cancer	0.000714	0.00362	CcSEcCtD
Dihydroergotamine—Hypertension—Vincristine—colon cancer	0.000709	0.00359	CcSEcCtD
Dihydroergotamine—Myalgia—Vincristine—colon cancer	0.0007	0.00354	CcSEcCtD
Dihydroergotamine—Hypertension—Irinotecan—colon cancer	0.000691	0.0035	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Capecitabine—colon cancer	0.000676	0.00342	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Methotrexate—colon cancer	0.000676	0.00342	CcSEcCtD
Dihydroergotamine—Discomfort—Irinotecan—colon cancer	0.000673	0.00341	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Capecitabine—colon cancer	0.000672	0.0034	CcSEcCtD
Dihydroergotamine—Oedema—Vincristine—colon cancer	0.000671	0.0034	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Capecitabine—colon cancer	0.000666	0.00337	CcSEcCtD
Dihydroergotamine—Confusional state—Irinotecan—colon cancer	0.000659	0.00334	CcSEcCtD
Dihydroergotamine—Oedema—Irinotecan—colon cancer	0.000653	0.00331	CcSEcCtD
Dihydroergotamine—Myalgia—Fluorouracil—colon cancer	0.000653	0.00331	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Vincristine—colon cancer	0.000648	0.00328	CcSEcCtD
Dihydroergotamine—Epistaxis—Capecitabine—colon cancer	0.000646	0.00327	CcSEcCtD
Dihydroergotamine—Discomfort—Fluorouracil—colon cancer	0.000645	0.00327	CcSEcCtD
Dihydroergotamine—Shock—Irinotecan—colon cancer	0.000643	0.00326	CcSEcCtD
Dihydroergotamine—Anorexia—Vincristine—colon cancer	0.000639	0.00324	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Irinotecan—colon cancer	0.000631	0.0032	CcSEcCtD
Dihydroergotamine—Confusional state—Fluorouracil—colon cancer	0.000631	0.0032	CcSEcCtD
Dihydroergotamine—Hypotension—Vincristine—colon cancer	0.000627	0.00317	CcSEcCtD
Dihydroergotamine—Oedema—Fluorouracil—colon cancer	0.000626	0.00317	CcSEcCtD
Dihydroergotamine—Anorexia—Irinotecan—colon cancer	0.000623	0.00315	CcSEcCtD
Dihydroergotamine—Rhinitis—Capecitabine—colon cancer	0.000617	0.00312	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Capecitabine—colon cancer	0.000612	0.0031	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000611	0.0031	CcSEcCtD
Dihydroergotamine—Pharyngitis—Capecitabine—colon cancer	0.000611	0.00309	CcSEcCtD
Dihydroergotamine—Tachycardia—Fluorouracil—colon cancer	0.000611	0.00309	CcSEcCtD
Dihydroergotamine—Hypotension—Irinotecan—colon cancer	0.00061	0.00309	CcSEcCtD
Dihydroergotamine—Insomnia—Vincristine—colon cancer	0.000607	0.00307	CcSEcCtD
Dihydroergotamine—Paraesthesia—Vincristine—colon cancer	0.000602	0.00305	CcSEcCtD
Dihydroergotamine—Anorexia—Fluorouracil—colon cancer	0.000596	0.00302	CcSEcCtD
Dihydroergotamine—Visual impairment—Capecitabine—colon cancer	0.000593	0.003	CcSEcCtD
Dihydroergotamine—Insomnia—Irinotecan—colon cancer	0.000591	0.00299	CcSEcCtD
Dihydroergotamine—Paraesthesia—Irinotecan—colon cancer	0.000586	0.00297	CcSEcCtD
Dihydroergotamine—Hypotension—Fluorouracil—colon cancer	0.000585	0.00296	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vincristine—colon cancer	0.000583	0.00295	CcSEcCtD
Dihydroergotamine—Dyspnoea—Irinotecan—colon cancer	0.000582	0.00295	CcSEcCtD
Dihydroergotamine—Somnolence—Irinotecan—colon cancer	0.000581	0.00294	CcSEcCtD
Dihydroergotamine—Fatigue—Vincristine—colon cancer	0.000578	0.00293	CcSEcCtD
Dihydroergotamine—Dyspepsia—Irinotecan—colon cancer	0.000575	0.00291	CcSEcCtD
Dihydroergotamine—Tinnitus—Capecitabine—colon cancer	0.000574	0.00291	CcSEcCtD
Dihydroergotamine—Pain—Vincristine—colon cancer	0.000574	0.00291	CcSEcCtD
Dihydroergotamine—Flushing—Capecitabine—colon cancer	0.000571	0.00289	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00057	0.00289	CcSEcCtD
Dihydroergotamine—Decreased appetite—Irinotecan—colon cancer	0.000568	0.00288	CcSEcCtD
Dihydroergotamine—Insomnia—Fluorouracil—colon cancer	0.000566	0.00287	CcSEcCtD
Dihydroergotamine—Fatigue—Irinotecan—colon cancer	0.000563	0.00285	CcSEcCtD
Dihydroergotamine—Paraesthesia—Fluorouracil—colon cancer	0.000562	0.00285	CcSEcCtD
Dihydroergotamine—Pain—Irinotecan—colon cancer	0.000559	0.00283	CcSEcCtD
Dihydroergotamine—Dyspnoea—Fluorouracil—colon cancer	0.000558	0.00283	CcSEcCtD
Dihydroergotamine—Somnolence—Fluorouracil—colon cancer	0.000556	0.00282	CcSEcCtD
Dihydroergotamine—Chills—Capecitabine—colon cancer	0.000552	0.0028	CcSEcCtD
Dihydroergotamine—Dyspepsia—Fluorouracil—colon cancer	0.000551	0.00279	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vincristine—colon cancer	0.000548	0.00278	CcSEcCtD
Dihydroergotamine—Decreased appetite—Fluorouracil—colon cancer	0.000544	0.00275	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Irinotecan—colon cancer	0.000538	0.00273	CcSEcCtD
Dihydroergotamine—Pain—Fluorouracil—colon cancer	0.000535	0.00271	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Irinotecan—colon cancer	0.000534	0.00271	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—colon cancer	0.000532	0.00269	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vincristine—colon cancer	0.00053	0.00269	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vincristine—colon cancer	0.00053	0.00269	CcSEcCtD
Dihydroergotamine—Abdominal pain—Irinotecan—colon cancer	0.000516	0.00262	CcSEcCtD
Dihydroergotamine—Body temperature increased—Irinotecan—colon cancer	0.000516	0.00262	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Fluorouracil—colon cancer	0.000515	0.00261	CcSEcCtD
Dihydroergotamine—Muscle spasms—Capecitabine—colon cancer	0.000515	0.00261	CcSEcCtD
Dihydroergotamine—Tremor—Capecitabine—colon cancer	0.000502	0.00254	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Capecitabine—colon cancer	0.000497	0.00252	CcSEcCtD
Dihydroergotamine—Urticaria—Fluorouracil—colon cancer	0.000497	0.00252	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—colon cancer	0.000496	0.00251	CcSEcCtD
Dihydroergotamine—Body temperature increased—Fluorouracil—colon cancer	0.000495	0.0025	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vincristine—colon cancer	0.000494	0.0025	CcSEcCtD
Dihydroergotamine—Malaise—Capecitabine—colon cancer	0.000483	0.00245	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—colon cancer	0.000481	0.00244	CcSEcCtD
Dihydroergotamine—Vertigo—Capecitabine—colon cancer	0.000481	0.00244	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Irinotecan—colon cancer	0.000481	0.00244	CcSEcCtD
Dihydroergotamine—Asthenia—Vincristine—colon cancer	0.000481	0.00244	CcSEcCtD
Dihydroergotamine—Palpitations—Capecitabine—colon cancer	0.000473	0.0024	CcSEcCtD
Dihydroergotamine—Asthenia—Irinotecan—colon cancer	0.000469	0.00237	CcSEcCtD
Dihydroergotamine—Hypertension—Capecitabine—colon cancer	0.000462	0.00234	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Fluorouracil—colon cancer	0.000461	0.00233	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vincristine—colon cancer	0.000459	0.00232	CcSEcCtD
Dihydroergotamine—Myalgia—Capecitabine—colon cancer	0.000456	0.00231	CcSEcCtD
Dihydroergotamine—Arthralgia—Capecitabine—colon cancer	0.000456	0.00231	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—colon cancer	0.000455	0.0023	CcSEcCtD
Dihydroergotamine—Anxiety—Capecitabine—colon cancer	0.000454	0.0023	CcSEcCtD
Dihydroergotamine—Discomfort—Capecitabine—colon cancer	0.000451	0.00228	CcSEcCtD
Dihydroergotamine—Diarrhoea—Irinotecan—colon cancer	0.000447	0.00226	CcSEcCtD
Dihydroergotamine—Dry mouth—Capecitabine—colon cancer	0.000446	0.00226	CcSEcCtD
Dihydroergotamine—Dizziness—Vincristine—colon cancer	0.000443	0.00225	CcSEcCtD
Dihydroergotamine—Pruritus—Fluorouracil—colon cancer	0.000443	0.00224	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—colon cancer	0.000441	0.00224	CcSEcCtD
Dihydroergotamine—Confusional state—Capecitabine—colon cancer	0.000441	0.00223	CcSEcCtD
Dihydroergotamine—Oedema—Capecitabine—colon cancer	0.000437	0.00221	CcSEcCtD
Dihydroergotamine—Dizziness—Irinotecan—colon cancer	0.000432	0.00219	CcSEcCtD
Dihydroergotamine—Shock—Capecitabine—colon cancer	0.00043	0.00218	CcSEcCtD
Dihydroergotamine—Diarrhoea—Fluorouracil—colon cancer	0.000428	0.00217	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—colon cancer	0.000427	0.00216	CcSEcCtD
Dihydroergotamine—Tachycardia—Capecitabine—colon cancer	0.000427	0.00216	CcSEcCtD
Dihydroergotamine—Vomiting—Vincristine—colon cancer	0.000426	0.00216	CcSEcCtD
Dihydroergotamine—Rash—Vincristine—colon cancer	0.000423	0.00214	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Capecitabine—colon cancer	0.000423	0.00214	CcSEcCtD
Dihydroergotamine—Dermatitis—Vincristine—colon cancer	0.000422	0.00214	CcSEcCtD
Dihydroergotamine—Headache—Vincristine—colon cancer	0.00042	0.00213	CcSEcCtD
Dihydroergotamine—Anorexia—Capecitabine—colon cancer	0.000417	0.00211	CcSEcCtD
Dihydroergotamine—Vomiting—Irinotecan—colon cancer	0.000415	0.0021	CcSEcCtD
Dihydroergotamine—Dizziness—Fluorouracil—colon cancer	0.000414	0.0021	CcSEcCtD
Dihydroergotamine—Rash—Irinotecan—colon cancer	0.000412	0.00209	CcSEcCtD
Dihydroergotamine—Dermatitis—Irinotecan—colon cancer	0.000411	0.00208	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—colon cancer	0.000411	0.00208	CcSEcCtD
Dihydroergotamine—Headache—Irinotecan—colon cancer	0.000409	0.00207	CcSEcCtD
Dihydroergotamine—Hypotension—Capecitabine—colon cancer	0.000408	0.00207	CcSEcCtD
Dihydroergotamine—Nausea—Vincristine—colon cancer	0.000398	0.00202	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000398	0.00202	CcSEcCtD
Dihydroergotamine—Vomiting—Fluorouracil—colon cancer	0.000398	0.00201	CcSEcCtD
Dihydroergotamine—Insomnia—Capecitabine—colon cancer	0.000395	0.002	CcSEcCtD
Dihydroergotamine—Rash—Fluorouracil—colon cancer	0.000394	0.002	CcSEcCtD
Dihydroergotamine—Dermatitis—Fluorouracil—colon cancer	0.000394	0.002	CcSEcCtD
Dihydroergotamine—Paraesthesia—Capecitabine—colon cancer	0.000393	0.00199	CcSEcCtD
Dihydroergotamine—Headache—Fluorouracil—colon cancer	0.000392	0.00199	CcSEcCtD
Dihydroergotamine—Dyspnoea—Capecitabine—colon cancer	0.00039	0.00197	CcSEcCtD
Dihydroergotamine—Nausea—Irinotecan—colon cancer	0.000388	0.00197	CcSEcCtD
Dihydroergotamine—Dyspepsia—Capecitabine—colon cancer	0.000385	0.00195	CcSEcCtD
Dihydroergotamine—Decreased appetite—Capecitabine—colon cancer	0.00038	0.00192	CcSEcCtD
Dihydroergotamine—Fatigue—Capecitabine—colon cancer	0.000377	0.00191	CcSEcCtD
Dihydroergotamine—Pain—Capecitabine—colon cancer	0.000374	0.00189	CcSEcCtD
Dihydroergotamine—Nausea—Fluorouracil—colon cancer	0.000372	0.00188	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—colon cancer	0.00037	0.00187	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Capecitabine—colon cancer	0.00036	0.00182	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—colon cancer	0.00036	0.00182	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—colon cancer	0.000358	0.00181	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Capecitabine—colon cancer	0.000357	0.00181	CcSEcCtD
Dihydroergotamine—Urticaria—Capecitabine—colon cancer	0.000347	0.00176	CcSEcCtD
Dihydroergotamine—Abdominal pain—Capecitabine—colon cancer	0.000346	0.00175	CcSEcCtD
Dihydroergotamine—Body temperature increased—Capecitabine—colon cancer	0.000346	0.00175	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—colon cancer	0.000339	0.00172	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—colon cancer	0.000339	0.00172	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—colon cancer	0.000335	0.0017	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—colon cancer	0.000328	0.00166	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Capecitabine—colon cancer	0.000322	0.00163	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—colon cancer	0.000315	0.00159	CcSEcCtD
Dihydroergotamine—Asthenia—Capecitabine—colon cancer	0.000314	0.00159	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—colon cancer	0.00031	0.00157	CcSEcCtD
Dihydroergotamine—Pruritus—Capecitabine—colon cancer	0.000309	0.00157	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—colon cancer	0.000304	0.00154	CcSEcCtD
Dihydroergotamine—Diarrhoea—Capecitabine—colon cancer	0.000299	0.00152	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000296	0.0015	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—colon cancer	0.000294	0.00149	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—colon cancer	0.000292	0.00148	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—colon cancer	0.00029	0.00147	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—colon cancer	0.000289	0.00147	CcSEcCtD
Dihydroergotamine—Dizziness—Capecitabine—colon cancer	0.000289	0.00146	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—colon cancer	0.000286	0.00145	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—colon cancer	0.000283	0.00143	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—colon cancer	0.000281	0.00142	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—colon cancer	0.000278	0.00141	CcSEcCtD
Dihydroergotamine—Vomiting—Capecitabine—colon cancer	0.000278	0.00141	CcSEcCtD
Dihydroergotamine—Rash—Capecitabine—colon cancer	0.000276	0.0014	CcSEcCtD
Dihydroergotamine—Dermatitis—Capecitabine—colon cancer	0.000275	0.00139	CcSEcCtD
Dihydroergotamine—Headache—Capecitabine—colon cancer	0.000274	0.00139	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—colon cancer	0.000268	0.00136	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—colon cancer	0.000266	0.00135	CcSEcCtD
Dihydroergotamine—Nausea—Capecitabine—colon cancer	0.00026	0.00132	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—colon cancer	0.000259	0.00131	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—colon cancer	0.000257	0.0013	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—colon cancer	0.000257	0.0013	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—colon cancer	0.00024	0.00121	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—colon cancer	0.000233	0.00118	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—colon cancer	0.00023	0.00117	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—colon cancer	0.000223	0.00113	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—colon cancer	0.000215	0.00109	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—colon cancer	0.000207	0.00105	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—colon cancer	0.000205	0.00104	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—colon cancer	0.000205	0.00104	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—colon cancer	0.000204	0.00103	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—colon cancer	0.000193	0.000979	CcSEcCtD
